2026

Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refractory Multiple Myeloma-A Multicenter Analysis
Al-Bazaz M, Alsdorf W, Leypoldt L, Sonnemann P, Schaefers C, Artzenroth J, Harzer M, Kamili A, Bartke L, Cords L, Vorwerk J, Leitner T, Maulhardt M, Brinkert K, Brioli A, Richardson T, Holtick U, Hillmann S, Salwender H, Khandanpour C, Bokemeyer C, Weisel K, Kosch R
AM J HEMATOL. 2026;101(7):1433-1439.

Adaptive bridging and holding therapy frequently reduces tumor burden and is associated with reduced toxicity after CAR-T cell therapy in multiple myeloma: A single-center real-world experience
Artzenroth J, Kosch R, Al-Bazaz M, Bartke L, Cords L, Güsmer C, Harzer M, Heinrich F, Kamili A, Leypoldt L, Madanchi R, Monin M, Schaefers C, Schlemmer T, Seibel J, Bokemeyer C, Weisel K, Alsdorf W
TRANSPL CELL THER. 2026 [Epub ahead of print].

Transplantation Strategies in Treatment of Primary Plasma Cell Leukemia in Germany-A Multi-Center Analysis
Dampmann M, Flossdorf S, Keyl J, Leitner T, Khandanpour C, Maulhardt M, Shumilov E, Stelljes M, Leypoldt L, Harzer M, Schaefers C, Ayuk F, von Tresckow B, Boquoi A, Schroeder T, Reinhardt H, Hanoun C
EUR J HAEMATOL. 2026 [Epub ahead of print].

Clinical scores to predict toxicities and outcomes in patients with multiple myeloma undergoing bispecific T-cell engager therapy
Frenking J, Riedhammer C, Hielscher T, Schaefers C, Leypoldt L, Harzer M, Sedloev D, Landrin V, Kehl N, Friedrich M, Zhou X, Steinhardt M, Weis P, Mersi J, Waldschmidt J, Weinhold N, Kortüm K, Müller-Tidow C, Einsele H, Sauer S, Weisel K, Richardson T, Teipel R, Rasche L, Raab M
BLOOD CANCER DISCOV. 2026;7(3):479-495.

Characteristics, treatment regimens, and outcomes of patients with true extramedullary multiple myeloma: a real-world monocentric analysis
Harzer M, Gross-Fengels N, Melzer F, Molwitz I, Kosch R, Al-Bazaz M, Artzenroth J, Cords L, Bartke L, Kamili A, Alsdorf W, Bokemeyer C, Weisel K, Leypoldt L, Schaefers C
ANN HEMATOL. 2026;105(7):.

2025

Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement
Steinhardt M, Schaefers C, Leypoldt L, Blau I, Harzer M, Zhou X, Riedhammer C, Kamili A, Kosch R, Topp L, Molwitz I, Gross-Fengels N, Melzer Y, Artzenroth J, Al-Bazaz M, Alsdorf W, Topp M, Duell J, Mersi J, Waldschmidt J, Bokemeyer C, Einsele H, Kortüm K, Weisel K, Rasche L
BLOOD CANCER J. 2025;15(1):126.

Correction: Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement
Steinhardt M, Schaefers C, Leypoldt L, Blau I, Harzer M, Zhou X, Riedhammer C, Kamili A, Kosch R, Topp L, Molwitz I, Gross-Fengels N, Melzer Y, Artzenroth J, Al-Bazaz M, Alsdorf W, Topp M, Duell J, Mersi J, Waldschmidt J, Bokemeyer C, Einsele H, Kortüm K, Weisel K, Rasche L
BLOOD CANCER J. 2025;15(1):.

Letzte Aktualisierung aus dem FIS: 19.09.2026 - 00:31 Uhr